Cervical cancer is the fourth most common cancer among women worldwide and is induced by a persistent infection with one of the high-risk strains of the human papilloma virus (HPV), most frequently HPV16 and/or HPV18.^[@bib1],\ [@bib2]^ Several types of cervical tumor histology can be distinguished, but the most commonly applied stratification is squamous cell carcinoma *vs* adenocarcinoma, both with different oncogenic mutations,^[@bib3],\ [@bib4]^ and different immunological tumor microenvironment.^[@bib5],\ [@bib6],\ [@bib7]^ Despite these substantial differences, current treatment modalities are the same for both squamous cell carcinomas and adenocarcinomas.^[@bib8]^ At present, patients with cervical cancer are treated with radical hysterectomy and pelvic lymphadenectomy or chemoradiation, depending on tumor stage and tumor size.^[@bib8],\ [@bib9],\ [@bib10]^ Unfortunately, the number of patients with adenocarcinoma is still rising and these patients seem to have a poorer survival rate than squamous cell carcinoma patients, especially if adenocarcinoma present with tumor-positive lymph nodes.^[@bib11],\ [@bib12],\ [@bib13],\ [@bib14]^ To improve the prognosis of cervical cancer patients, novel immunotherapeutic strategies need to be developed and established. In addition, histological subtype-specific treatment needs to be considered, which requires a detailed investigation of the tumor microenvironment in relation to clinical outcome of these tumor types.

Promising immunotherapeutic therapies targeting immune checkpoint molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) expressed on activated T cells, counteract the immunosuppressive cycle prevailing in the tumor microenvironment and have led to complete and long-lasting clinical responses.^[@bib15],\ [@bib16]^ Also, anti-programmed cell death ligand 1 (PD-L1) therapy has been associated with improved survival outcome in several types of cancer, including lung cancer, melanoma, renal cell cancer, and bladder cancer.^[@bib17],\ [@bib18]^ At present, in advanced cervical cancer, clinical phase I/II trials are ongoing examining the effects of ipilimumab (anti-CTLA-4; NCT01711515), pembrolizumab (anti-PD-1; NCT02054806), and nivolumab (anti-PD-1; NCT02488759); however, no study results have been reported yet.

Recently, we have identified a suppressive myeloid cell subset expressing PD-L1, with high and interrelated rates of regulatory T cells in metastatic lymph nodes of patients with cervical cancer.^[@bib19]^ Currently, information is largely lacking about PD-L1 expression patterns in primary and metastatic cervical tumors. Therefore, we investigated the expression of PD-L1 in primary and metastatic cervical cancer in relation to the two major histological subtypes (squamous cell carcinoma and adenocarcinoma), and studied the correlation with pathological and clinical characteristics in two patient cohorts. This study provides more insight into the role of PD-L1 in cervical cancer, and strengthens the rationale for blocking the PD-L1/PD-1 immunosuppressive axis.

Materials and methods
=====================

Study Group
-----------

Formalin-fixed, paraffin-embedded material was collected from two different patient cohorts. Patient cohort I consisted of 156 squamous cell carcinomas and 49 adenocarcinomas primary tumor samples from the Leiden University Medical Center (Leiden, The Netherlands), and patient cohort II consisted of 96 squamous cell carcinomas and 31 adenocarcinomas paired primary and metastatic tumor samples from the Academic Medical Center (Amsterdam, The Netherlands), VU University Medical Center (Amsterdam, The Netherlands), or Leiden University Medical Center (Leiden, The Netherlands). Patients in both cohorts underwent surgery as primary treatment between 1985--2008 and the patient characteristics are shown in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, respectively. Patient samples were handled and used in accordance with the medical ethical guidelines described in the Code of Conduct for Proper Secondary Use of Human Tissue of the Dutch Federation of Biomedical Scientific Societies.

Immunohistochemistry
--------------------

Immunohistochemical staining was performed with an automated Ventana immunostainer (Ventana Medical Systems, Tucson, AZ, USA) as previously described using Cell Conditioning 1 Solution (Ventana Medical Systems) as antigen retrieval, 1:200 rabbit anti-PD-L1 antibody for 48 min at 36 °C (clone E1L3N; Cell Signaling, Danvers, MA, USA), and using the OptiView DAB IHC Detection Kit (Ventana Medical Systems).^[@bib20]^

For triple immunofluorescence staining on four squamous cell carcinoma patients from cohort I, 1:100 rabbit anti-PD-L1 (clone SP142; Spring Bioscience, Pleasanton, CA, USA), 1:25 mouse IgG2a anti-CD14 (clone 7; Abcam, Cambridge, UK), and 1:100 mouse IgG1 anti-CD163 (clone 10D6; Novocastra, Milton Keynes, UK) were used and detected with Alexa Fluor 647 goat anti-rabbit, Alexa Fluor 546 goat anti-mouse IgG2a, and Alexa Fluor 488 goat anti-mouse IgG1 (all from Life Technologies, Grand Island, NY, USA), as described previously.^[@bib20]^

Imaging, Scoring, and Analysis
------------------------------

The immunohistochemically PD-L1-stained slides were analyzed and imaged using a bright-field microscope (Olympus BX50; Olympus, Center Valley, PA, USA). Tumor fields were distinguished from normal tissue by the use of nuclear staining with hematoxylin. Primary and metastatic tumor cells were designated PD-L1 positive, when ≥5% of the tumor cells were positive for PD-L1. Moreover, in both primary and metastatic tumor samples, a distinction was made between diffuse (throughout the whole tumor) or marginal (peripheral staining, on the interface between tumor and stroma) expression of PD-L1 by the tumor cells; scores were given for the presence of PD-L1-positive tumor-infiltrating cells (yes/no), and for immune cells accumulated around tumor fields forming a PD-L1-positive cordon (yes/no). In primary cervical cancer samples, semiquantitative scores were given for PD-L1-positive stromal cells (low numbers/high numbers). In metastatic lymph node samples, scores were obtained for resident lymph node tissue adjacent to metastases (peritumoral) or distant from metastases (paracortical areas) (low numbers/high numbers). Stromal cells and histiocytes present in B-cell follicles were used as an internal control for PD-L1 positivity.

The immunofluorescence was analyzed and imaged using a digital imaging fluorescence microscope (Axiovert-200M; Zeiss, Oberkochen, Germany). Tumor fields were distinguished from normal tissue by the use of DAPI staining.

Statistical Analysis
--------------------

The statistical analyses were performed with IBM SPSS (IBM, Armonk, NY, USA) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). The Pearson\'s *χ*^2^ or Fisher\'s exact tests were used for the comparison of PD-L1 expression between squamous cell carcinoma and adenocarcinoma, and clinicopathological characteristics. Kaplan--Meier 5-year survival curves were generated and log-rank analyses were performed. Primary tumors and paired metastatic lymph nodes were compared with the McNemar test. *P*-values below 0.05 were considered statistically significant.

Results
=======

PD-L1 Protein Expression in Primary Cervical Cancer
---------------------------------------------------

Representative examples of different PD-L1 expression patterns in primary cervical tumors (patient cohort I, see [Table 1](#tbl1){ref-type="table"}) are depicted in [Figure 1](#fig1){ref-type="fig"} and the results are summarized in [Table 3](#tbl3){ref-type="table"}. We observed PD-L1 positivity in tumor cells, in tumor-infiltrating immune cells, and in stromal immune cells. All tumor-infiltrating and the majority of stromal PD-L1-positive immune cells were identified as tumor-associated macrophages, being double positive for CD163 and PD-L1 and/or triple positive for CD163, CD14, and PD-L1 ([Figure 2](#fig2){ref-type="fig"}). PD-L1 positivity was observed in \>5% (used as cutoff) of the tumor cells in 54% of the squamous cell carcinomas and in 14% of all adenocarcinomas (*P*\<0.001). In addition, PD-L1-positive tumor-associated macrophages were present in 53% of the squamous cell carcinomas and in 12% of the adenocarcinomas (*P*\<0.001) ([Table 3](#tbl3){ref-type="table"}). For stromal PD-L1-positive immune cells and aggregates of PD-L1-positive cells at the tumor stroma interface (termed as PD-L1-positive cordon), no significant differences were found between squamous cell carcinomas and adenocarcinomas.

PD-L1 Expression in Relation to Clinicopathological Characteristics and Survival
--------------------------------------------------------------------------------

PD-L1 expression was analyzed in relation to clinicopathological characteristics for patient cohort I. Interestingly, we found the majority of PD-L1-positive squamous cell carcinoma more often to be HPV18-positive than HPV16-positive squamous cell carcinomas (83% HPV18 *vs* 42% HPV16; *P*\<0.001). In squamous cell carcinoma, tumors with over 15 mm infiltration depth had more often low numbers of PD-L1-positive cells in stroma (*P*=0.025). In adenocarcinoma, although the group sizes were small, patients with a PD-L1-positive cordon presented with a high FIGO stage (\>IBII) (*P*=0.010). No further significant correlations were found for PD-L1 positivity and clinicopathological characteristics (tumor size, parametrium invasion, vaginal involvement, and lymph node involvement).

In addition, log-rank tests were performed and Kaplan--Meier plots were generated for disease-free survival and disease-specific survival of the two histological subtypes to assess the correlation with PD-L1 positivity. Squamous cell carcinoma patients with diffuse PD-L1 expression or patients with PD-L1-negative tumors had worse disease-free survival (*P*=0.022 and *P*=0.029, respectively) and disease-specific survival (*P*=0.046 and *P*=0.096, respectively) compared with patients with marginal PD-L1 expression in the primary tumor ([Figures 3a and b](#fig3){ref-type="fig"}). In squamous cell carcinoma patients, no significant association was found between PD-L1-positive tumor-associated macrophages and survival ([Figure 3c](#fig3){ref-type="fig"}), whereas adenocarcinoma patients with PD-L1-positive tumor-associated macrophages had a significantly worse disease-specific survival (*P*=0.014) compared with adenocarcinoma patients without PD-L1-positive tumor-associated macrophages ([Figure 3d](#fig3){ref-type="fig"}).

PD-L1 Expression in Primary Tumor and Paired Metastatic Lymph Node
------------------------------------------------------------------

Next, we studied PD-L1 expression by immunohistochemistry in patient cohort II with samples available from primary and paired metastatic lymph nodes from patients with squamous cell carcinoma and adenocarcinoma ([Table 2](#tbl2){ref-type="table"}). The results for cohort II are summarized in [Table 4](#tbl4){ref-type="table"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. In the primary tumor, in correspondence to the results obtained in cohort I, squamous cell carcinomas were more often positive for PD-L1 (*P*=0.024) and had more often PD-L1-positive tumor-associated macrophages (*P*=0.012). In addition, 25% of the squamous cell carcinomas had a strong PD-L1-positive cordon, compared with 3% of the adenocarcinomas (*P*=0.012) ([Table 4](#tbl4){ref-type="table"}).

In the metastatic lymph nodes, PD-L1 positivity was detected in tumor cells, tumor-associated macrophages, immune cells surrounding the metastasis in peritumoral areas, immune cells in resident T-cell areas, and in germinal center histiocytes. Representative examples of PD-L1 expression in metastatic cervical lymph nodes are depicted in [Figures 4a and b](#fig4){ref-type="fig"}. No significant difference was found in PD-L1 expression patterns between squamous cell carcinoma and adenocarcinoma metastatic lymph nodes ([Table 4](#tbl4){ref-type="table"}).

Next, we compared PD-L1 expression between primary tumors and paired metastases. Discordant tumor cell staining of PD-L1 between primary tumor cells and metastatic tumor cells was found for squamous cell carcinomas in 22 of 71 (31%) cases and for adenocarcinomas in 5 of 28 (18%) cases ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Nevertheless, overall in squamous cell carcinoma and adenocarcinoma patients, no significant differences was found between primary tumors and paired metastatic lymph nodes in PD-L1 positivity of tumor cells, diffuse and marginal PD-L1 expression, the presence of PD-L1-positive tumor-associated macrophages, and the presence of a PD-L1-positive cordon ([Figures 4c--e and g](#fig4){ref-type="fig"}). In both squamous cell carcinomas and adenocarcinomas, more dense cordons of PD-L1-positive immune cells were found surrounding the metastases compared with the paired primary tumors (*P*=0.001 for squamous cell carcinoma and *P*=0.041 for adenocarcinoma) ([Figure 4f](#fig4){ref-type="fig"}).

Discussion
==========

New immunotherapies targeting the PD-1/PD-L1 axis have been reported to give very promising clinical responses in patients with various types of cancer.^[@bib17],\ [@bib21],\ [@bib22],\ [@bib23],\ [@bib24]^ However, until now no data are available on the clinical efficacy of blocking this checkpoint in cervical cancer. PD-L1 positivity has been reported previously in cervical intraepithelial neoplasias and cervical carcinomas,^[@bib25],\ [@bib26],\ [@bib27]^ and, recently, we have reported on the presence of PD-L1-positive immune cells in tumor-draining lymph nodes, including metastasis-free and metastatic lymph nodes.^[@bib19],\ [@bib20]^ However, extensive studies on PD-L1 expression in a large patient cohort of primary and paired metastatic cervical cancer samples, in relation to histological subtype and clinicopathological patient characteristics, are lacking.

In the present study, we observed diverse, heterogeneous PD-L1 expression patterns among primary tumors from patients with cervical cancer. Although, there are controversies concerning the use of different PD-L1 antibody clones, several studies have shown that the clones used in the present study are specific and validated for immunohistochemical assays.^[@bib28],\ [@bib29]^ Apart from the tumor cells, we also observed PD-L1 positivity in immune cells present in the tumor fields and in the stromal compartment. In more than 20% of the tumors, we observed a PD-L1-positive cordon which was also described in other tumor types.^[@bib30],\ [@bib31]^ These PD-L1-positive immune cells might have an immunosuppressive effect by inhibiting T-cell function^[@bib32]^ or might be a sign of immune activation, in conjunction with the costimulatory markers CD80 and CD86 as expressed on mature dendritic cells.^[@bib33]^ We identified these PD-L1-positive immune cells as CD163^+^ and/or CD14^+^ tumor-associated macrophages, whereas, remarkably, another study on cervical cancer claimed them to consist mainly of CD8^+^ T cells.^[@bib27]^ The presence of PD-L1^+^ T cells was also reported by other studies; however, in these studies compelling evidence in the form of double stainings was lacking,^[@bib17],\ [@bib34]^ and, therefore, it is more likely that PD-L1-positive tumor-infiltrating cells are from myeloid origin with an M2 macrophage-like phenotype as observed by us, which is in accordance with multiple other studies.^[@bib31],\ [@bib35],\ [@bib36]^ Similar M2-like cells, conditioned by tumor-derived soluble factors, have been shown to be poor CD8^+^ T-cell primers, potent inducers of FoxP3^+^ regulatory T cells and proangiogenic- and protumor-invasive factor producers facilitating tumor progression.^[@bib37],\ [@bib38]^ Although different myeloid cell sub-populations and a low CTL/regulatory T-cell ratio have been found to correlate to survival in the cervical tumor microenvironment,^[@bib39],\ [@bib40]^ the precise role of PD-L1-positive tumor-associated macrophages is yet to be fully elucidated. Nevertheless, *in vitro* observations by Heusinkveld *et al.*,^[@bib41]^ suggest that cervical cancer-derived IL-6 and prostaglandin-E2 convert monocytes to T-cell-tolerizing macrophages with low levels of costimulatory molecules and IL-12p70, and high levels of IL-10 and PD-L1 expression consistent with a poor ability to prime naïve T cells. In accordance, we have previously shown that high IL-6 in the tumor microenvironment of cervical cancer is associated with poor patient survival.^[@bib42],\ [@bib43]^

This is the first study to report on the difference in PD-L1 expression between squamous cell carcinoma and adenocarcinoma. Two previous publications on PD-L1 expression in cervical cancer did not include adenocarcinoma patients in the cohorts analyzed.^[@bib25],\ [@bib27]^ Strikingly, we observed prognostic differences for PD-L1 expression patterns between squamous cell carcinoma and adenocarcinoma patients; we found significantly more PD-L1 expression by tumor cells (cutoff \>5%) and higher rates of PD-L1-positive tumor-associated macrophages in squamous cell carcinomas as compared with adenocarcinomas. Similarly, differential findings for PD-L1 expression in the two histological subtypes were reported in lung cancer patients.^[@bib35],\ [@bib44]^

Earlier studies have reported conflicting data on correlations between PD-L1 expression in different solid tumor types with both improved^[@bib30],\ [@bib45],\ [@bib46]^ and poor prognosis.^[@bib47],\ [@bib48],\ [@bib49],\ [@bib50],\ [@bib51]^ However, recent meta-analyses have shown a predominant correlation with poor survival.^[@bib52],\ [@bib53],\ [@bib54]^ We were not able to detect an association between PD-L1 expression *per se* and survival, which is in accordance with an earlier study in patients with cervical cancer, analyzing the whole cohort through the use of tissue microarrays.^[@bib25]^ Of note, we did find an unambiguous survival benefit for squamous cell carcinoma patients with marginal PD-L1 tumor expression (at the tumor--stromal interface) as compared with patients with diffusely positive PD-L1 tumors. In head and neck cancer, diffuse PD-L1 expression was detected in only 1/14 tumors, whereas marginal PD-L1 expression was detected in 13/14 tumors, but no survival analysis was performed.^[@bib31]^ Marginal PD-L1 expression might be induced by extrinsic factors, such as IFN*γ*, TNF*α*, and IL-1*β* locally produced by juxtaposed T lymphocytes, whereas diffuse PD-L1 expression is more likely to result from constitutive expression because of underlying tumor-intrinsic molecular mechanisms such as PTEN loss and aberrant JAK/STAT signaling.^[@bib24],\ [@bib30],\ [@bib55]^ Importantly, conjunction with infiltrating effector T cells and the release of type-1 effector cytokines might explain the observed association between marginal expression of PD-L1 and a more favorable prognosis (see [Figures 3a and b](#fig3){ref-type="fig"}). Recently, we reported on a survival benefit for cervical cancer patients with high numbers of Tbet-positive T cells, indicative of high IFN*γ* production.^[@bib56]^

In adenocarcinoma, we observed a survival benefit for patients with tumor lacking PD-L1-positive tumor-associated macrophages. These findings point to a difference in immunological microenvironments and tumor escape mechanisms between cervical adenocarcinoma and squamous cell carcinoma in line with previous reports on histology-specific oncogenic mutations,^[@bib3],\ [@bib4]^ and immunological profiles.^[@bib5],\ [@bib6],\ [@bib7]^

Our findings suggest that targeting the PD-1/PD-L1 pathway might be a promising immunotherapy approach in patients with cervical cancer, as PD-L1 is expressed in 54% of the squamous cell carcinomas. In addition, recent studies have shown that even patients with PD-L1-negative primary tumors, including lung cancer, gastric cancer, colorectal cancer, renal cell cancer, and bladder cancer and melanoma, respond to anti-PD-L1 treatment.^[@bib18],\ [@bib24],\ [@bib57]^ This might be due to the observed heterogeneous and discordant PD-L1 tumor cell staining between primary tumor cells and metastatic tumor cells with, in some cases, PD-L1-positive metastases originating from PD-L1-negative primary tumors (see [Supplementary Table 1](#sup1){ref-type="supplementary-material"}), which was also observed in clear-cell renal cell carcinoma.^[@bib58],\ [@bib59]^ Adenocarcinoma patients with PD-L1-positive tumor-associated macrophages had a poor survival; however, anti-PD-1 or anti-PD-L1 therapy might be successful, as in bladder cancer patients with PD-L1-positive tumor-infiltrating immune cells objective responses were obtained after anti-PD-L1 therapy.^[@bib18]^ Of note, patient stratification on the basis of PD-L1-positive tumor-associated macrophages is very important in this regard, as patients with adenocarcinoma infiltrated by PD-L1-positive tumor-associated macrophages represented a relatively small minority (see [Table 4](#tbl4){ref-type="table"}).

In conclusion, this study showed that PD-L1 was more frequently expressed by squamous cell carcinoma than by adenocarcinoma. Diffuse PD-L1 expression in squamous cell carcinoma patients was correlated with poor disease-free survival and disease-specific survival compared with marginal PD-L1 expression, which was associated with a remarkably favorable prognosis. In adenocarcinoma patients, the presence of PD-L1-positive tumor-associated macrophages was associated with a poor disease-specific survival as compared with patients without PD-L1-positive tumor-associated macrophages. Our data thus suggest that targeting the PD-1/PD-L1 pathway may be therapeutically efficacious and should be considered in the treatment of cervical cancer patients.
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![Programmed death-ligand 1 (PD-L1) expression patterns in cervical cancer. Different patterns for PD-L1 expression (in brown) were detected in primary squamous cell carcinoma and adenocarcinoma. (**a**) Diffuse PD-L1 expression by primary squamous cell carcinoma cells. (**b**) Marginal PD-L1 expression by primary squamous cell carcinoma cells. (**c**) PD-L1-negative primary squamous cell carcinoma. (**d**) Primary squamous cell carcinoma with PD-L1-positive tumor-associated macrophages (examples indicated by black arrows). (**e**) PD-L1-negative primary adenocarcinoma. (**f**) PD-L1-negative primary adenocarcinoma with PD-L1-positive tumor-associated macrophages (examples indicated by black arrows). Scale bar is 100 *μ*m.](modpathol201664f1){#fig1}

![Identification of programmed death-ligand 1 (PD-L1)-positive tumor-associated macrophages. A representative triple immunofluorescence staining shows monochromatic (**a**) PD-L1, (**b**) CD14, (**c**) CD163 images, and (**d**) colocalized PD-L1 (in blue), CD14 (in red), CD163 (in green), and DAPI (4\',6-diamidino-2-phenylindole) (in gray) in cervical cancer patients with PD-L1-positive tumor-associated macrophages in primary tumors. NB: Varying intensity of CD163 staining can be observed. Scale bar is 30 *μ*m.](modpathol201664f2){#fig2}

![Survival analysis for PD-L1 positivity. Kaplan--Meier 5-year survival curves show disease-free survival (DFS) (**a**) and disease-specific survival (DSS) (**b**) for patients with diffuse PD-L1 expression by tumor cells, for patients with PD-L1-negative (PD-L1−) tumors, and for patients with marginal PD-L1 expression in squamous cell carcinoma. Kaplan--Meier 5-year survival curve shows disease-specific survival (DSS) for patients with (**c**) squamous cell carcinoma and (**d**) adenocarcinoma with PD-L1-positive tumor-associated macrophages (TAM(+)) and for patients without PD-L1-positive tumor-associated macrophages (TAM(−)). *P*-values were calculated using the log-rank test.](modpathol201664f3){#fig3}

![PD-L1 expression in metastatic lymph nodes. PD-L1 (in brown) expression in (**a**) metastatic squamous cell carcinoma with a PD-L1-positive cordon indicated by the black arrow and high numbers of PD-L1-positive peritumoral immune cells, and (**b**) metastatic adenocarcinoma lymph node samples. PD-L1 positivity in primary squamous cell carcinoma (SCC) and adenocarcinoma (AC) and metastatic lymph nodes (**c**) with PD-L1-positive tumor cells, (**d**) with diffuse PD-L1 expression, (**e**) with the presence of PD-L1-positive tumor-associated macrophages (TAM), (**f**) with the presence of peritumoral PD-L1-positive immune cells, and (**g**) with the presence of a PD-L1-positive cordon. \*\**P*=0.001 and \**P*=0.041 calculated with McNemar test. Scale bar is 50 *μ*m.](modpathol201664f4){#fig4}

###### Clinicopathological characteristics of patient cohort I

  *Clinicopathological characteristics*                       *SCC*       *AC*
  -------------------------------------------------------- ------------ ---------
  Number of patients                                           156         49
                                                                             
  *Age*                                                                 
   Mean                                                         48         41
   Min                                                          22         26
   Max                                                          87         72
                                                                             
  *FIGO stage*[a](#t1-fn2){ref-type="fn"}                               
   IBI                                                      93 (59.5)    41 (84)
   ≥IBII                                                     62 (40)     8 (16)
   Missing                                                   1 (0.5)      0 (0)
                                                                             
  *HPV status*[a](#t1-fn2){ref-type="fn"}                               
   HPV 16                                                    97 (62)     18 (37)
   HVP18                                                     24 (15)     19 (39)
   Other                                                     25 (16)      4 (8)
   Negative                                                   10 (7)     8 (16)
                                                                             
  *Tumor size*[a](#t1-fn2){ref-type="fn"}                               
   ≤4 cm                                                     61 (39)     39 (80)
   \>4 cm                                                    74 (47)     10 (20)
   Unknown                                                   21 (14)      0 (0)
                                                                        
  *Parametrium invasion*[a](#t1-fn2){ref-type="fn"}                     
   Yes                                                       26 (17)      4 (8)
   No                                                        128 (82)    45 (92)
   Unknown                                                    2 (1)       0 (0)
                                                                             
  *Lymph node metastases*[a](#t1-fn2){ref-type="fn"}                    
   Yes                                                       50 (32)     13 (27)
   No                                                       105 (67.5)   36 (73)
   Unknown                                                   1 (0.5)      0 (0)
                                                                        
  *Recurrence within 5 years*[a](#t1-fn2){ref-type="fn"}                
   Yes                                                       45 (29)     15 (31)
   No                                                        111 (71)    34 (69)

Abbreviations: AC, adenocarcinoma; FIGO, International Federation of Gynecology and Obstetrics; SCC, squamous cell carcinoma.

Data shown as *n* (%).

###### Clinicopathological characteristics of patient cohort II

  *Clinicopathological characteristics*                                   *SCC*       *AC*
  --------------------------------------------------------------------- ---------- ----------
  Number of patients                                                        96         31
                                                                                        
  *Age*                                                                            
   Mean                                                                     44         41
   Min                                                                      24         23
   Max                                                                      81         66
                                                                                   
  *FIGO stage*[a,](#t2-fn2){ref-type="fn"}[b](#t2-fn3){ref-type="fn"}              
   IBI                                                                   58 (60)    16 (52)
   ≥IBII                                                                 37 (39)    15 (48)
   Missing                                                                1 (1)      0 (0)
                                                                                        
  *Tumor size*[a](#t2-fn2){ref-type="fn"}                                          
   ≤4 cm                                                                 27 (28)    11 (36)
   \>4 cm                                                                68 (71)    29 (61)
   Unknown                                                                1 (1)      1 (3)
                                                                                        
  *Parametrium invasion*[a](#t2-fn2){ref-type="fn"}                                
   Yes                                                                   35 (37)     8 (26)
   No                                                                    59 (61)    22 (71)
   Unknown                                                                2 (2)      1 (3)
                                                                                        
  *Lymph node metastases*[a](#t2-fn2){ref-type="fn"}                               
   Yes                                                                   96 (100)   31 (100)
   No                                                                     0 (0)      0 (0)
                                                                                        
  *Recurrence within 5 years*[a](#t2-fn2){ref-type="fn"}                           
   Yes                                                                   30 (31)    14 (45)
   No                                                                    61 (64)    13 (42)
   Missing                                                                5 (5)      4 (13)

Abbreviations: AC, adenocarcinoma; FIGO, International Federation of Gynecology and Obstetrics; SCC, squamous cell carcinoma.

Data shown as *n* (%).

NB: HPV status is not known for this patient cohort.

###### PD-L1 expression in patient cohort I

                           *SCC*                                *AC*                                P*-value*
  ------------------------ ------------------------------------ ----------------------------------- ---------------
  *Tumor cells*                                                                                     
   PD-L1+ (\>5%)           83 (54)                              7 (14)                               
   PD-L1−                  71 (46)                              42 (86)                             ***\<0.001***
   Diffuse PD-L1           71 (87)                              4 (80)                               
   Margin PD-L1            11 (13)[a](#t3-fn3){ref-type="fn"}   1 (20)[a](#t3-fn3){ref-type="fn"}   *0.533*
                                                                                                     
  *PD-L1+ TAM*                                                                                      
   Yes                     79 (53)                              6 (12)                               
   No                      70 (47)                              43 (88)                             ***\<0.001***
                                                                                                     
  *Stromal PD-L1+ cells*                                                                            
   High numbers            122 (78)                             31 (65)                              
   Low numbers             34 (22)                              17 (35)                             *0.057*
                                                                                                     
  *PD-L1+ cordon*                                                                                   
   Yes                     38 (25)                              7 (15)                               
   No                      116 (75)                             41 (85)                             *0.142*

Abbreviations: AC, adenocarcinoma; PD-L1+, PD-L1 positive; PD-L1−, PD-L1 negative; PD-L1+ TAM, PD-L1-positive TAMs in tumor fields; PD-L1+ cordon, PD-L1-positive immune cells accumulated around tumor fields; SCC, squamous cell carcinoma; TAM, tumor-associated macrophage.

*P*-value was calculated with *χ*^2^ test, or in case of \<5 cases per group with Fisher\'s exact test.

In some PD-L1-positive tumors (*n*=1 for SCC and *n*=2 for AC), we found the staining pattern not convincing because of a small tumor field, and excluded those cases for scoring diffuse or marginal expression pattern. Numbers in bold are statistical significant (*P*\<0.05). Numbers in italic are not statistical significant.

###### PD-L1 expression in patient cohort II

                               *Primary tumor*   *Metastatic tumor*                                                     
  ---------------------------- ----------------- ------------------------------------ ------------- --------- --------- ---------
  *Tumor cells*                                                                                                         
   PD-L1+ (\>5%)               33 (39)           5 (17)                                             21 (26)   3 (10)     
   PD-L1−                      51 (61)           25 (83)                              ***0.024***   60 (74)   26 (90)   *0.116*
   Diffuse PD-L1               27 (82)           4 (100)[a](#t4-fn3){ref-type="fn"}                 12 (63)   2 (67)     
   Margin PD-L1                6 (18)            0 (0)                                *1*           7 (37)    1 (33)    *1*
                                                                                                                         
  *PD-L1+ TAM*                                                                                                          
   Yes                         24 (29)           2 (7)                                              21 (26)   3 (10)     
   No                          59 (71)           28 (93)                              ***0.012***   60 (74)   26 (90)   *0.116*
                                                                                                                         
  *Peritumoral PD-L1+ cells*                                                                                            
   High numbers                40 (49)           11 (37)                                            62 (77)   22 (76)    
   Low numbers                 42 (51)           19 (63)                              ***0.254***   19 (23)   7 (24)    1
                                                                                                                         
  *PD-L1+ cordon*                                                                                                       
   Yes                         20 (25)           1 (3)                                              20 (25)   4 (14)     
   No                          61 (75)           28 (97)                              ***0.012***   61 (75)   24 (86)   *0.301*

Abbreviations: AC, adenocarcinoma; PD-L1+, PD-L1 positive; PD-L1−, PD-L1 negative; PD-L1+ TAM, PD-L1-positive TAMs in tumor fields; peritumoral immune cells, PD-L1-positive immune cells in the vicinity of metastatic tumor fields; PD-L1+ cordon, PD-L1-positive immune cells accumulated around tumor fields; SCC, squamous cell carcinoma; TAM, tumor-associated macrophage.

*P*-value was calculated with *χ*^2^ test, or in case of \<5 cases per group with Fisher\'s exact test.

In one AC PD-L1+ tumor, we found the staining pattern not convincing because of a small tumor field, and excluded this case for scoring diffuse or marginal expression pattern. Numbers in bold are statistical significant (*P*\<0.05). Numbers in italic are not statistical significant.
